Abstract:
The present invention provides a process for the preparation of the stereoisomers of 1-aminoalkylphosphonic acids and of 1-aminoalkylphosphinic acids by enzymatic resolution of their racemic N-acyl derivatives and subsequent deacylation, wherein the enzymatic resolution is carried out with penicillin G amidase.
Abstract:
A process for obtaining D-2-(6-methoxy-2-naphthyl)-propionic acid from a mixture of D- and L-2-(6-methoxy-2-naphthyl)-propionic acid lower alkyl esters is provided by asymmetric hydrolysis of the L-ester with a microbial enzyme, separation of the 2-(6-methoxy-2-naphthyl)-propionic acid from the D-2-(6-methoxy-2-naphthyl)-propionic acid lower alkyl ester and saponification of the latter, wherein the saponification is carried out enzymatically with esterase from hog liver or from Pleurotus ostreatus.
Abstract:
The present invention provides a stabilized sarcosine oxidase preparation which contains creatineamidinohydrolase covalently bound to a water-soluble polysaccharide.
Abstract:
The present invention provides a process for the determination of the .beta.-lipoprotein fraction (LDL) in body fluids, especially in serum or plasma, wherein the LDL fraction is selectively precipitated from the sample by the addition of a polyvinyl sulphate with monovalent cations and then determined.The present invention also provides a reagent for the determination of the .beta.-lipoprotein fraction (LDL) in body fluids, especially in serum or plasma, wherein it contains polyvinyl sulphate.
Abstract:
Method of direct determination of beta-lipoproteins in a blood sample containing pre-beta-lipoprotein, (VLDL) alpha-lipoprotein (HDL), and beta-lipoprotein (LDL), comprising mixing the blood plasma or serum of the blood sample with a solid, water-insoluble anion exchanger operable to retain the pre-beta-lipoprotein (VLDL) and the alpha-lipoprotein (HDL) to remove them from solution, separating the blood plasma or serum from the anion exchanger and thereafter determining the amount of beta-lipoprotein (LDL) remaining in solution.
Abstract:
The present invention provides liver uricase, wherein it is covalently bond to a water-soluble polysaccharide, polyacid anhydride, polyvinylpyrrolidone or acid anhydride as carrier substance and is still soluble at pH values below 6.The present invention also provides a process for the preparation of this liver uricase.